|Bid||1,545.00 x 346500|
|Ask||1,546.00 x 57900|
|Day's Range||1,545.00 - 1,568.00|
|52 Week Range||15.44 - 1,568.00|
|PE Ratio (TTM)||-6,606.84|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
On a per-share basis, the Ness Ziona, Israel-based company said it had net income of 13 cents. Earnings, adjusted for stock option expense, came to 14 cents per share. The biopharmaceutical posted revenue ...
Kamada Ltd.'s (KMDA) decided to withdraw the marketing authorization application (MAA) for its inhaled formulation of Alpha-1 Antitrypsin (AAT) in the EU.
Categories: Europe Value Analsysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Kamada Ltd. a score of 57. Our analysis is based on comparing Kamada Ltd. with the following peers – Compugen Ltd., BioCancell Ltd., XTL Biopharmaceuticals Ltd. and RedHill Biopharma Ltd. (CGEN-IL, BICL-IL, XTLB-IL and RDHL-IL). Investment Outlook Kamada Ltd. has a fundamental score of 57 and has ... Read more (Read more...)